AstraZeneca Pharma India Limited has submitted to the Exchange, the financial results for the period ended March 31, 2025.
ASTRAZEN · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 15.9 pts more than Nifty Microcap 250 and 16.1 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
AstraZeneca Pharma India Limited has submitted its financial results for the period ended March 31, 2025 to the NSE. This is a routine quarterly/annual results filing required of all listed companies under SEBI regulations. The detailed figures — including revenue, operating profit, net profit, and margins — would be contained in the full results document, which is not included in the excerpt provided. Investors should refer to the attached detailed results for specific numbers and year-on-year comparisons.
The submission itself is a procedural compliance filing and is not directly price-moving. Any meaningful stock reaction will depend on how the actual numbers (revenue growth, margins, profit) compare with market expectations, which cannot be assessed from this announcement alone.